Mosanna Therapeutics develops a nasal spray for treating obstructive sleep apnea.
Mosanna Therapeutics has raised $80.0M in total funding. The most recent round was Series A. The last funding was announced in June 2025.
Mosanna Therapeutics's investors include Norwest, HTGF (High-Tech Gruenderfonds), Forbion Capital Partners, EQT Life Sciences, Pivotal bioVenture Partners.
Mosanna Therapeutics is headquartered in Redwood City, United States.
Mosanna Therapeutics develops a nasal spray for treating obstructive sleep apnea.
Mosanna Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Mosanna Therapeutics — Funding & Investors." VCBacked, June 9, 2025, https://www.vcbacked.co/company/mosanna-therapeutics. Accessed July 20, 2026.
VCBacked. (2025). Mosanna Therapeutics — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/mosanna-therapeutics
{{cite web |title=Mosanna Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/mosanna-therapeutics |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated